453 related articles for article (PubMed ID: 15640818)
21. BMT for severe aplastic anemia using cyclosporine.
May WS; Sensenbrenner LL; Burns WH; Ambinder R; Carroll MP; Griffin CA; Jones RJ; Miller CB; Mellits ED; Vogelsang GB
Bone Marrow Transplant; 1993 Jun; 11(6):459-64. PubMed ID: 8334426
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin.
Inagaki J; Nagatoshi Y; Kawano Y; Saito Y; Takahashi D; Nagayama J; Shinkoda Y; Hirata H; Okamura J
Pediatr Transplant; 2007 Mar; 11(2):180-6. PubMed ID: 17300498
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
24. Transplantation of related and unrelated umbilical cord blood stem cells in Austria. Austrian Working Party for Stem Cell Transplantation. Austrian Society of Hematology and Oncology.
Schwinger W; Urban C; Lackner H; Kerbl R; Sovinz P; Gardner H; Peters C; Niederwieser D; Fink FM; Kögler G
Wien Klin Wochenschr; 1999 May; 111(9):348-53. PubMed ID: 10407995
[TBL] [Abstract][Full Text] [Related]
25. Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant.
Godder KT; Mehta J; Chiang KY; Adams S; van Rhee F; Singhal S; Higgins-Smith K; O'Neal W; DeRienzo S; Henslee-Downey JP
Bone Marrow Transplant; 2001 Dec; 28(11):1031-6. PubMed ID: 11781612
[TBL] [Abstract][Full Text] [Related]
26. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
27. Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia.
Reiter E; Keil F; Brugger S; Kalhs P; Rabitsch W; Hinterberger W; Fischer G; Rosenmayr A; Haas O; Volc B; Lechner K; Greinix HT
Bone Marrow Transplant; 1997 Jun; 19(12):1191-6. PubMed ID: 9208112
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation.
Gillio AP; Boulad F; Small TN; Kernan NA; Reyes B; Childs BH; Brochstein JA; Laver J; Castro-Malaspina H; O'Reilly RJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):18-24. PubMed ID: 9209737
[TBL] [Abstract][Full Text] [Related]
29. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
[TBL] [Abstract][Full Text] [Related]
30. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
31. The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia.
Lee JW; Cho BS; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Min WS; Park CW
Biol Blood Marrow Transplant; 2011 Jan; 17(1):101-8. PubMed ID: 20601037
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen.
Hale GA; Bowman LC; Woodard JP; Cunningham JM; Benaim E; Horwitz EM; Heslop HE; Krance RA; Leung W; Shearer PD; Handgretinger R
Bone Marrow Transplant; 2003 Jun; 31(11):981-6. PubMed ID: 12774048
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party.
Bacigalupo A; Hows J; Gordon-Smith EC; Gluckman E; Van Lint MT; Congiu M; James DC; Barrett AJ; Gmur J; De Planque MM
Bone Marrow Transplant; 1988 Nov; 3(6):531-5. PubMed ID: 3063321
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
[TBL] [Abstract][Full Text] [Related]
35. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
[TBL] [Abstract][Full Text] [Related]
37. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
[TBL] [Abstract][Full Text] [Related]
38. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease.
Ho VT; Kim HT; Li S; Hochberg EP; Cutler C; Lee SJ; Fisher DC; Milford E; Kao G; Daley H; Levin J; Ng A; Mauch P; Alyea EP; Antin JH; Soiffer RJ
Bone Marrow Transplant; 2004 Dec; 34(11):987-94. PubMed ID: 15489873
[TBL] [Abstract][Full Text] [Related]
39. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
Novitzky N; Thomas V; du Toit C; McDonald A
Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]